Medium-Chain Fatty Acids with Gemcitabine for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for pancreatic cancer are limited by toxicity and drug resistance, leading to poor prognosis and limited treatment options for metastatic pancreatic cancer patients.
Innovation Solution
The use of medium-chain length fatty acids, their salts, or triglycerides in combination with gemcitabine or gemcitabine and erlotinib to treat pancreatic cancer, offering a synergistic antitumor activity that reduces toxicity and delays drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapeutic agents are used to treat pancreatic cancer, then tumor growth inhibition is achieved, but toxicity and drug resistance increase
Solution Approach 1:
The patent changes the chemical structure parameter of chemotherapeutic agents by using medium-chain length fatty acid derivatives (C6-C10) instead of conventional chemotherapy drugs. This structural modification maintains antitumor efficacy while reducing toxicity to normal cells and delaying drug resistance development.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining medium-chain length fatty acid derivatives with gemcitabine or erlotinib. This composite treatment synergistically enhances tumor growth inhibition while the fatty acid component reduces the toxic side effects of the chemotherapeutic agents.
2Reliability
If standard chemotherapeutic agents are used to treat pancreatic cancer, then tumor growth inhibition is achieved, but drug resistance develops
Solution Approach 1:
The patent modifies the chemical parameters of the therapeutic agent by using medium-chain length fatty acid derivatives with specific chain lengths (C6-C10). This parameter change allows the drug to maintain efficacy against pancreatic cancer cells while preventing the biochemical adaptations that lead to drug resistance.
Solution Approach 2:
The patent applies medium-chain length fatty acid derivatives as a preliminary or combination treatment before or with conventional chemotherapy. This preliminary action sensitizes cancer cells to treatment and prevents the development of resistance mechanisms, extending the duration of drug efficacy.
3Reliability
If chemotherapy is used to treat cancer, then cancer cells are killed, but rapidly proliferating normal cells are also damaged
Solution Approach 1:
The patent imparts local quality to the therapeutic agent by designing medium-chain length fatty acid derivatives that specifically interact with pancreatic cancer cell membranes or metabolic pathways. This localized action allows selective targeting of cancer cells while sparing rapidly proliferating normal cells from toxic damage.
Solution Approach 2:
The patent changes the physicochemical parameters of the therapeutic agent to medium-chain length fatty acid derivatives, which have different metabolic handling and cellular uptake characteristics compared to conventional chemotherapy drugs. This parameter change enables selective accumulation in cancer cells, reducing damage to normal cells.
Data Source
AI summary
The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n=6-10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium-chain length fatty acid/triglyceride compounds include capric acid, sodium caprate, tricaprin, lauric acid, sodium laurate, and trilaurin.